目的 探讨血钙水平与急性脑出血(AICH)患者血肿体积、卒中严重程度及预后的关系.方法 72例急性脑出血患者,根据其血钙水平的不同分为A组(血钙水平<2.15 mmol/L,20例)、B组(血钙水平2.15～2.50 mmol/L,26例)和C组(血钙水平>2.50 mmol/L,26例).检测三组患者的血肿体积、美国国立卫生研究院卒中量表(NIHSS)评分以及预后改良的Rankin量表(mRS)评分,分析急性脑出血患者的血钙含量和与血肿体积、卒中程度以及预后效果之间的关系.结果 A组患者血肿体积为(13.04±2.42)ml、NIHSS评分为(15.05±5.07)分、mRS评分为(8.32±2.07)分,B组分别为(11.36±2.28)ml、(11.64±8.04)分、(14.55±1.50)分,C组分别为(9.65±2.57)ml、(10.36±4.18)分、(14.73±2.06)分;A组患者的血肿体积大于B组和C组,NIHSS评分高于B组和C组,mRS评分低于B组和C组,差异具有统计学意义(P<0.05).A组患者死亡8例,死亡率为40.0％(8/20);B组患者死亡3例,死亡率为11.54％(3/26);C组患者死亡1例,死亡率为3.85％(1/26);A组患者死亡率显著高于B组和C组,差异具有统计学意义(P<0.05).结论 对于急性脑出血患者而言血钙水平越低则证明患者血肿体积越大,相应的病情程度和预后效果均较差.

Objective To study the effect of deanxit combined with oryzanol injection on life quality,anxiety and depression in elderly cerebral infarction patients.Methods 90 elderly cerebral infarction patients were divided into deanxit group (27 cases)(Group A),oryzanol injection group (28 cases) (Group B) and deanxit joint oryzanol injection combined treatment group (35 cases) (Group C) according random number method during August 2012 to March 2015.Aher four weeks of treatment,life quality,anxiety and depression were compared in each group before and after treatment.Results After treatment,the score of physiological function,bodily pain,general health,vitality,social functioning,mental health,physical function,emotional function in Group A,Group B and Group C were significantly higher than before treatment (P ＜ 0.05).After treatment,the score of physiological function,body pain,general health,vitality,social functioning,mental health,physical function,emotional function in Group C were significant higher than Group A and Group B (P ＜ 0.05).The score of HAMD and HAMA after treatment in the Group C was the lowest among the three groups (P ＜ 0.05).Conclusion Deanxit combined with oryzanol injection can significantly improve the life quality and reduce patient anxiety and depression in patients wiith first elderly cerebral infarction.

目的:探讨导致颅内静脉窦血栓患者发生脑梗死的危险因素.方法:选取2011年10月至2015年8月期间我院收治的80例颅内静脉窦血栓患者作为研究对象.根据这80例患者发生脑梗死的情况将其分为脑梗死组(36例)和非脑梗死组(44例).笔者对两组患者的临床资料进行回顾性分析,从中找出导致颅内静脉窦血栓患者发生脑梗死的危险因素.结果:脑梗死组患者发生颅内静脉窦血栓至接受治疗的时间平均为(55.22±28.02)天,非脑梗死组患者发生颅内静脉窦血栓至接受治疗的时间平均为(20.22±8.19)天.与非脑梗死组患者相比,脑梗死组患者发生颅内静脉窦血栓至接受治疗的时间更长,差异有统计学意义(P<0.05).在脑梗死组患者中,急性颅内静脉窦血栓患者有25例(占69.44%),亚急性颅内静脉窦血栓患者和慢性颅内静脉窦血栓患者共有11例(占30.56%).在非脑梗死组患者中,急性颅内静脉窦血栓患者有10例(占22.72%),亚急性颅内静脉窦血栓患者和慢性颅内静脉窦血栓患者共有34例(占77.28%).与非脑梗死组患者相比,脑梗死组患者中急性颅内静脉窦血栓患者的占比更高,差异有统计学意义(P<0.05).在脑梗死组患者中,上矢状窦处存在静脉血栓的患者有33例,横窦处存在静脉血栓的患者有32例.在非脑梗死组患者中,上矢状窦处存在静脉血栓的患者有26例,横窦处存在静脉血栓的患者有25例.与非脑梗死组患者相比,脑梗死组患者中上矢状窦处和横窦处存在静脉血栓的患者的人数更多,差异有统计学意义(P<0.05).结论:颅内静脉窦血栓患者出现静脉血栓至接受治疗的时间较长、其颅内静脉窦血栓为急性、其颅内静脉血栓分布于上矢状窦处和横窦处是导致其发生脑梗死的危险因素.临床医生应对上述情况予以关注.